328 related articles for article (PubMed ID: 15562128)
21. Serogroup A meningococcal conjugate vaccines in Africa.
Kristiansen PA; Jørgensen HJ; Caugant DA
Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
[TBL] [Abstract][Full Text] [Related]
22. Serogroup C meningococcal conjugate vaccines: new preparations. Effective from age two months.
Prescrire Int; 2003 Apr; 12(64):43-6. PubMed ID: 12675020
[TBL] [Abstract][Full Text] [Related]
23. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
[TBL] [Abstract][Full Text] [Related]
24. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
Papaevangelou V; Spyridis N
Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
[TBL] [Abstract][Full Text] [Related]
26. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
[TBL] [Abstract][Full Text] [Related]
27. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study.
Cardoso CW; Ribeiro GS; Reis MG; Flannery B; Reis JN
PLoS One; 2015; 10(4):e0123734. PubMed ID: 25874777
[TBL] [Abstract][Full Text] [Related]
29. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
[TBL] [Abstract][Full Text] [Related]
30. Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil.
Cardoso CW; Pinto LL; Reis MG; Flannery B; Reis JN
Vaccine; 2012 Aug; 30(37):5541-6. PubMed ID: 22749604
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.
De Wals P; Deceuninck G; De Serres G; Boivin JF; Duval B; Remis R; Massé R
Clin Infect Dis; 2005 Apr; 40(8):1116-22. PubMed ID: 15791510
[TBL] [Abstract][Full Text] [Related]
32. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
33. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
Arnold R; Galloway Y; McNicholas A; O'Hallahan J
Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
[TBL] [Abstract][Full Text] [Related]
35. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of a mass immunization campaign against serogroup C meningococci in children in the federal state of Santa Catarina, Brazil.
Kupek E; Puricelli RC; Westrupp MH
Braz J Infect Dis; 2001 Dec; 5(6):324-31. PubMed ID: 11980595
[TBL] [Abstract][Full Text] [Related]
37. Impact of meningococcal vaccination with combined serogroups A and C polysaccharide vaccine on carriage of Neisseria meningitidis C.
Fernández S; Arreaza L; Santiago I; Malvar A; Berrón S; Vazquez JA; Hervada X
J Med Microbiol; 2003 Jan; 52(Pt 1):75-77. PubMed ID: 12488569
[TBL] [Abstract][Full Text] [Related]
38. Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.
Pascucci MG; Di Gregori V; Frasca G; Rucci P; Finarelli AC; Moschella L; Borrini BM; Cavrini F; Liguori G; Sambri V; Bonanni P; Fantini MP
Hum Vaccin Immunother; 2014; 10(3):671-6. PubMed ID: 24384537
[TBL] [Abstract][Full Text] [Related]
39. Long-term impacts of MenC vaccination campaign in the Salvador, Brazil metropolitan region: A comparison of pre- and post-vaccine periods.
Monalisa Mendes Dantas Sales N; Azevedo J; Teles Bastos Ribeiro M; Fonseca de Freitas H; Pedreira da Silva Filho H; Machado Cordeiro S; Galvão Reis M; Neves Reis J
Vaccine; 2020 Sep; 38(40):6267-6273. PubMed ID: 32741673
[TBL] [Abstract][Full Text] [Related]
40. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].
de Greeff SC; de Melker HE; Spanjaard L; van den Hof S; Dankert J
Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1132-5. PubMed ID: 12822525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
